These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 36076105

  • 1. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
    Link H, Thompson SF, Tian M, Haas JS, Meise D, Maas C, Dimitrov S.
    Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P.
    BMC Cancer; 2013 Aug 14; 13():386. PubMed ID: 23945072
    [Abstract] [Full Text] [Related]

  • 3. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L, Baser O, Kutikova L, Page JH, Barron R.
    Support Care Cancer; 2015 Nov 14; 23(11):3131-40. PubMed ID: 25821144
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 6. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM, Bias P, Buchner A.
    Support Care Cancer; 2016 Jan 08; 24(1):267-273. PubMed ID: 26024743
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Köhler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A.
    Support Care Cancer; 2021 May 08; 29(5):2519-2527. PubMed ID: 32944800
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
    Danova M, Chiroli S, Rosti G, Doan QV.
    Tumori; 2009 May 08; 95(2):219-26. PubMed ID: 19579869
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Gao L, Li SC.
    Breast Cancer; 2018 Nov 08; 25(6):671-680. PubMed ID: 29802592
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
    Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B.
    J Oncol Pharm Pract; 2018 Sep 08; 24(6):412-423. PubMed ID: 28614980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.
    Dtsch Med Wochenschr; 2010 Mar 08; 135(9):385-9. PubMed ID: 20180162
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M, Esteves S, André R, Isidoro M, Moreira A.
    Support Care Cancer; 2016 Feb 08; 24(2):597-603. PubMed ID: 26111956
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar 08; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.